CDK9 inhibitors push cancer cells over the edge

Matthew W Nowicki, Malcolm D Walkinshaw

Research output: Contribution to journalEditorialpeer-review


The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.
Original languageEnglish
Pages (from-to)1047-8
Number of pages2
JournalChemistry and Biology
Issue number10
Publication statusPublished - Oct 2010


Dive into the research topics of 'CDK9 inhibitors push cancer cells over the edge'. Together they form a unique fingerprint.

Cite this